VYNE Therapeutics to Participate in September Investor Conferences
VYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical company, has announced its participation in two significant investor conferences in September 2024. The company, which focuses on developing therapies for chronic inflammatory and immune-mediated conditions, will attend:
1. The H.C. Wainwright 26th Annual Global Investment Conference from September 9-11 in New York, NY, where they will engage in one-on-one investor meetings.
2. The Stifel 2024 Virtual Immunology and Inflammation Summit on September 17-18, featuring a fireside chat presentation on Tuesday, September 17 at 8:30 AM ET, along with one-on-one investor meetings.
A webcast of the Stifel presentation will be available, with a replay accessible on VYNE's website for 90 days post-event.
VYNE Therapeutics Inc. (Nasdaq: VYNE), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2024. L'azienda, che si concentra sullo sviluppo di terapie per condizioni infiammatorie croniche e mediate dal sistema immunitario, parteciperà a:
1. La 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright, che si terrà dal 9 all'11 settembre a New York, NY, dove parteciperanno a incontri individuali con gli investitori.
2. Il Summit Virtuale di Immunologia e Infiammazione 2024 di Stifel il 17 e 18 settembre, che includerà una presentazione in formato fireside chat martedì 17 settembre alle 8:30 AM ET, insieme a incontri individuali con gli investitori.
Un webcast della presentazione di Stifel sarà disponibile, con una replica accessibile sul sito web di VYNE per 90 giorni dopo l'evento.
VYNE Therapeutics Inc. (Nasdaq: VYNE), una compañía biofarmacéutica en etapa clínica, ha anunciado su participación en dos importantes conferencias de inversionistas en septiembre de 2024. La empresa, que se enfoca en desarrollar terapias para condiciones inflamatorias crónicas y mediadas por el sistema inmunológico, asistirá a:
1. La 26ª Conferencia Global de Inversión Anual H.C. Wainwright del 9 al 11 de septiembre en Nueva York, NY, donde participarán en reuniones individuales con inversores.
2. El Summit Virtual de Inmunología e Inflamación 2024 de Stifel los días 17 y 18 de septiembre, que contará con una presentación en un formato de charla junto a la chimenea el martes 17 de septiembre a las 8:30 AM ET, así como reuniones individuales con inversores.
Se disponibilizará un webcast de la presentación de Stifel, con una repetición accesible en el sitio web de VYNE durante 90 días después del evento.
VYNE Therapeutics Inc. (Nasdaq: VYNE), 임상 단계의 바이오 제약 회사,가 2024년 9월에 두 개의 중요한 투자자 회의에 참석할 것이라고 발표했습니다. 만성 염증 및 면역 매개 상태에 대한 치료제를 개발하는 데 중점을 두고 있는 이 회사는 다음 회의에 참석합니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 회의, 9월 9일부터 11일까지 뉴욕에서 열리며, 이곳에서 개별 투자자 미팅이 있을 예정입니다.
2. Stifel 2024 가상 면역학 및 염증 정상 회담, 9월 17일부터 18일까지 열리며, 9월 17일 화요일 오전 8:30 ET에 fireside chat 형식의 프레젠테이션이 있을 예정이며, 개별 투자자 미팅도 진행됩니다.
Stifel의 프레젠테이션 웹캐스트가 제공되며, 이벤트 후 90일 동안 VYNE의 웹사이트에서 재방송을 시청할 수 있습니다.
VYNE Therapeutics Inc. (Nasdaq: VYNE), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à deux importantes conférences d'investisseurs en septembre 2024. L'entreprise, qui se concentre sur le développement de thérapies pour des conditions inflammatoires chroniques et médiées par le système immunitaire, participera à :
1. La 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright du 9 au 11 septembre à New York, NY, où elle participera à des réunions individuelles avec des investisseurs.
2. Le Sommet Virtuel d'Immunologie et d'Inflammation 2024 de Stifel les 17 et 18 septembre, qui présentera une discussion en format fireside le mardi 17 septembre à 8h30 ET, ainsi que des réunions individuelles avec des investisseurs.
Un webcast de la présentation de Stifel sera disponible, avec une rediffusion accessible sur le site de VYNE pendant 90 jours après l'événement.
VYNE Therapeutics Inc. (Nasdaq: VYNE), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen, das sich auf die Entwicklung von Therapien für chronische Entzündungs- und immunvermittelte Erkrankungen konzentriert, wird an folgenden Veranstaltungen teilnehmen:
1. Der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September in New York, NY, wo sie an persönlichen Investorenmeetings teilnehmen werden.
2. Dem Stifel 2024 virtuellen Immunologie- und Entzündungsgipfel vom 17. bis 18. September, der am Dienstag, den 17. September, um 8:30 Uhr ET eine Fireside-Chat-Präsentation beinhalten wird, sowie persönliche Investorenmeetings.
Ein Webcast der Stifel-Präsentation wird verfügbar sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung auf der Website von VYNE zugänglich ist.
- None.
- None.
BRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that management will participate in two investor conferences in September:
H.C. Wainwright 26th Annual Global Investment Conference
September 9-11, 2024, New York, NY
Format: One-on-one investor meetings
Stifel 2024 Virtual Immunology and Inflammation Summit
September 17-18, 2024
Presentation: Tuesday, September 17, 2024 at 8:30 AM ET
Format: Fireside Chat and one-on-one investor meetings
Registration: Webcast link
A webcast replay will be available on the VYNE website for 90 days following the event.
About VYNE Therapeutics Inc.
VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE's unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.
For more information about VYNE Therapeutics Inc., or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
FAQ
What investor conferences will VYNE Therapeutics (VYNE) participate in during September 2024?
When is VYNE Therapeutics (VYNE) scheduled to present at the Stifel 2024 Virtual Immunology and Inflammation Summit?
Will there be a webcast available for VYNE Therapeutics' (VYNE) presentation at the Stifel conference?
What type of company is VYNE Therapeutics (VYNE)?
